A5044224344- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Cancer Treatment and Pharmacology
- Viral-associated cancers and disorders
- Drug Transport and Resistance Mechanisms
- Platelet Disorders and Treatments
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- Neutropenia and Cancer Infections
- CNS Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Retinoids in leukemia and cellular processes
- Click Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- HIV/AIDS drug development and treatment
University of Bologna
2013-2022
Istituto di Ematologia di Bologna
2006-2022
Azienda USL di Bologna
2022
Policlinico S.Orsola-Malpighi
2011-2021
Istituto Oncologico Romagnolo
2007-2020
National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov of the Ministry of Healthcare of the Russian Federation
2019
Fondazione Gimema Onlus
1994-2017
Heidelberg University
2006-2016
University Hospital Heidelberg
2009-2016
Johns Hopkins University
2016
Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no to interferon alfa. We compared efficacy imatinib that alfa combined low-dose cytarabine newly diagnosed CML.
The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML the phase. For 5 years, we followed patients with who received imatinib as initial therapy.We randomly assigned 553 receive then evaluated them overall event-free survival; progression accelerated-phase or blast crisis; hematologic, cytogenetic, molecular responses;...
Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has resulted in high rates of complete cytogenetic response and progression-free survival among patients chronic myeloid leukemia (CML) the phase, after failure imatinib treatment. We assessed efficacy safety as compared imatinib, for first-line treatment chronic-phase CML.In multinational study, 519 newly diagnosed CML were randomly assigned to receive dasatinib at dose 100 mg once daily (259 patients) or 400 (260...
Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on basis of more than 10 years follow-up in CML who were treated imatinib as initial therapy.In this open-label, multicenter trial crossover design, we randomly assigned newly diagnosed phase to receive either or interferon alfa plus cytarabine. Long-term included overall survival, response treatment, serious adverse events.The...
Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the inhibitor–refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted phase 2 trial ponatinib in patients chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic (Ph-positive ALL).
Purpose We report the 5-year analysis from phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia (CML) (CP) treated dasatinib or imatinib. Methods newly diagnosed CML-CP were randomly assigned to receive 100 mg once daily (n = 259) imatinib 400 260). Results At time study closure, 61% 63% dasatinib- imatinib-treated remained on initial...
In view of studies showing that interferon alfa was effective treatment for chronic myeloid leukemia and it prolonged survival, we organized a prospective, controlled comparative study this treatment.We compared recombinant alfa-2a with conventional chemotherapy (hydroxyurea or busulfan) in trial designed to have power 80 percent detect difference 20 median survival between the group given chemotherapy. Between 1986 1988, 322 patients previously untreated minimally treated Philadelphia...
Abstract Purpose: ABL kinase domain mutations have been implicated in the resistance to BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients. Experimental Design: Using denaturing high-performance liquid chromatography and sequencing, we screened for 370 Ph+ patients with evidence hematologic or cytogenetic imatinib. Results: Mutations were found 127 297 (43%) evaluable 27% chronic-phase (14% treated frontline; 31% post-IFN failure), 52% accelerated-phase...